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Abstract
Background
PIK3CA-related overgrowth spectrum (PROS) include a group of disorders that affect only
the terminal portion of a limb, such as type I macrodactyly, and conditions like fibroadipose
overgrowth (FAO), megalencephaly-capillary malformation (MCAP) syndrome, congenital li-
pomatous asymmetric overgrowth of the trunk, lymphatic, capillary, venous, and combined-
type vascular malformations, epidermal nevi, skeletal and spinal anomalies (CLOVES) syn-
drome and Hemihyperplasia Multiple Lipomatosis (HHML). Heterozygous postzygotic
PIK3CAmutations are frequently identified in these syndromes, while timing and tissue
specificity of the mutational event are likely responsible for the extreme phenotypic
variability observed.
Methods
We carried out a combination of Sanger sequencing and targeted deep sequencing of
genes involved in the PI3K/AKT/mTOR pathway in three patients (1 MCAP and 2 FAO) to
identify causative mutations, and performed immunoblot analyses to assay the phosphory-
lation status of AKT and P70S6K in affected dermal fibroblasts. In addition, we evaluated
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their ability to grow in the absence of serum and their response to the PI3K inhibitors wort-
mannin and LY294002 in vitro.
Results and Conclusion
Our data indicate that patients’ cells showed constitutive activation of the PI3K/Akt pathway.
Of note, PI3K pharmacological blockade resulted in a significant reduction of the prolifera-
tion rate in culture, suggesting that inhibition of PI3K might prove beneficial in future thera-
pies for PROS patients.
Introduction
In 1997 Cynthia A. Moore et al. [1] described a new sporadic overgrowth disorder with a com-
bination of anomalies including macrocephaly, megalencephaly, cutis marmorata telangiecta-
tica congenita and foot abnormalities different from the condition known as cutis marmorata
telangiectatica congenita.
In the following years, two megalencephaly (MEG) syndromes were recognized: the mega-
lencephaly-capillary malformation (MCAP) syndrome, formerly called macrocephaly-capillary
malformation (MCM) syndrome, characterized by involvement of the CNS, growth dysregula-
tion with body asymmetry (hemihyperplasia), vascular anomalies and distal limb malforma-
tions (polydactyly and syndactyly), and the closely related megalencephaly-polymicrogyria-
polydactyly-hydrocephalus (MPPH) syndrome, which lacks the vascular malformations and
syndactyly of MCAP. These two easily recognizable and sporadic conditions show similar
brain involvement with (hemi)megalencephaly, ventriculomegaly, polymicrogyria, and cere-
bellar tonsillar ectopia progressing to Chiari anomaly; this suggests that they are due to de novo
mutations of genes of the same pathway [2]. So far, PIK3CA postzygotic mutations have been
described in almost all cases of MCAP/MPPH, while mutations in the AKT3 and PIK3R2 genes
have been detected in a few cases [2]. Very recently, de novo heterozygous activating mutations
in the CCND2 gene (encoding cyclin D2) were identified in MPPH patients lacking upstream
PI3K/AKT pathway mutations [3].
Postzygotic mutations in the PIK3CA gene have also been identified in distinct overgrowth
syndromes such as CLOVES (congenital lipomatous asymmetric overgrowth of the trunk, lym-
phatic, capillary, venous, and combined-type vascular malformations, epidermal nevi, skeletal
and spinal anomalies), HHML (Hemihyperplasia Multiple Lipomatosis) and fibroadipose over-
growth (FAO) [4–6]. CLOVES syndrome differs fromMCAP syndrome for a more marked
growth dysregulation, with lipomatous tissues showing complex congenital overgrowth (typical-
ly appearing as a truncal lipomatous mass) and a combination of vascular and lymphatic malfor-
mations. FAO shares clinical and molecular features with CLOVES syndrome and may involve
the trunk or extremities. It is characterized by progressive segmental overgrowth in various re-
gions of the body including visceral, subcutaneous, muscular, fibroadipose, and skeletal tissues.
Recently, for all these clinical entities characterized by the presence of activating somatic
mutations in the PIK3CA gene, the new term of PIK3CA-Related Overgrowth Spectrum
(PROS) has been proposed so to comprehend the broad range of clinical manifestations in
these patients [7].
To identify causative mutations in three patients with clinical symptoms consistent with
PROS, we performed Sanger sequencing and targeted deep sequencing of 21 selected genes in-
volved in the PI3K/AKT/mTOR pathway in three patients, one affected by MCAP, and two by
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FAO. In three of them we identified a causative mutation in the PIK3CA gene, which encodes
the p110α catalytic subunit of the phosphoinositide-3-kinase heterodimer. Moreover, we eval-
uated the phosphorylation status of AKT and P70S6K in primary affected dermal fibroblasts
and assessed cell growth upon treatment with PI3K inhibitors.
Materials and Methods
Patient recruitment
All patients signed an informed consent approved by the local ethics committee to participate
in this study and to authorize the publication of clinical images. Blood and tissue samples were
collected during surgical debulking procedures performed for the treatment of FAO.
DNA Extraction and Sanger Sequencing
Genomic DNA was extracted from peripheral blood cells (PBCs) and tissue samples using the
QIAamp Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer’s instructions,
and quantified on a BioSpectrometer Plus (Eppendorf, Hamburg, Germany). The entire coding
regions of PIK3CA (RefSeq NM_006218.2), including all splice junctions and adjacent intronic
sequences were amplified by standard PCR protocols using the AmpliTaq Gold DNA Polymer-
ase (Applied Biosystems, London, UK) and the primer pairs listed in Table A in S1 File. Direct
sequencing was performed using the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied
Biosystems) according to the manufacturer’s instructions on an ABI 310 Genetic Analyzer
(Applied Biosystems).
Targeted Deep Sequencing
21 genes involved in the PI3K/AKT/mTOR pathway (PIK3R1, PIK3R2, PIK3CA, PTEN, PDK1,
PDK2, KRAS, AKT1, AKT2, AKT3, RICTOR,MAPKAP1,MLST8,MTOR, IRS1, GAB1, GAB2,
THEM4,MAPK8I1, PTPN11, RAPTOR) were selected for targeted sequencing, see Table B in
S1 File. An Ion AmpliSeq Custom Panel was designed online using Ion AmpliSeq Designer 2.2
(http://www.ampliseq.com/) to analyze the CDSs (+/-25 bp of intronic flanking regions) of
these genes. The final custom panel was composed of 554 amplicons divided into 2 primer
pools for a total of 66.58 kb of DNA. DNA was quantified using the Qubit dsDNA HS Assay
Kit (Life Technologies) on a Qubit2.0 Fluorometer (Life Technologies).
The panel covered 97.45% of the regions of interest (ROI). Libraries were prepared using
the Ion AmpliSeq Library Kit v2.0 (Life Technologies), according to the manufacturer's in-
structions. One of 16 barcodes of the Ion Xpress Barcode Adapters 1–16 Kit (Life Technolo-
gies) was added to each sample. Libraries were quantified with the Qubit dsDNA HS Assay Kit
(Life Technologies) on a Qubit2.0 Fluorometer (Life Technologies) and equimolar amounts of
each library were used to prepare templates for clonal amplification. Emulsion PCR was per-
formed on a OneTouch2 system (Life Technologies) using the Ion PGM Template OT2 200
Kit (Life Technologies). Templates were enriched using Ion OneTouch ES (Life Technologies)
and prepared for loading on a 316v2/318v2 chip. Groups of 4 sample libraries were sequenced
on each chip. Sequencing runs were performed on an Ion Torrent Personal Genome Machine
(Life Technologies) using the Ion PGM Sequencing 200 Kit v2 (Life Technologies), according
to the manufacturer’s instructions.
Alignment
Data analysis was performed using Torrent Suite Software v.4.0.2 (Life Technologies). Reads
were aligned to the hg19 human reference genome from the UCSC Genome Browser (http://
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genome.ucsc.edu/) and to the BED file designed using Ion AmpliSeq Designer. Alignments
were visually verified with the Integrative Genomics Viewer (IGV) v.2.3 (www.broadinstitute.
org/igv/home).
Coverage Analysis
The mean average read depth and the percentage of reads that mapped on the ROI out of the
total number of reads (reads on target) were calculated using the Coverage Analysis plugin
(Torrent Suite 4.0 software, Life Technologies). For each sample, the percentage of ROI with a
minimum coverage of 200X was calculated using the amplicon coverage matrix file.
Variant Analysis
Variant calling was performed with the Variant Caller plugin configured with somatic high
stringency parameters. Variants were annotated using the Ion Reporter 4.0 software (https://
ionreporter.lifetechnologies.com/ir/). Common single nucleotide variants (minor allele fre-
quency [MAF]>5%), exonic synonymous variants and intronic variants were removed from
the analysis, while exonic non-synonymous, splice site and loss-of-function variants were ana-
lyzed. The pathogenicity prediction programs PolyPhen2 and SIFT and splice prediction pro-
grams were used to evaluate variants not previously described.
Cell Culture and Reagents
IMR90 human primary fibroblasts (from ATCC) were grown in DMEM supplemented with
10% FBS, 100 IU/ml penicillin and 100 μg/ml streptomycin; patients-derived primary fibro-
blasts were grown in RPMI supplemented with 10% FBS, 100 IU/ml penicillin, 100 μg/ml
streptomycin and 1% L-glutamine in a humidified incubator at 37°C and 5% CO2 avoiding
confluence at any time. Wortmannin (10 μM) and LY294002 (25μM) were purchased from
Sigma-Aldrich (Poole, UK) and Selleckchem (Houston, TX), respectively.
Skin biopsies were washed in PBS, then transferred in a 35-mm petri plate containing 2 ml
of serum free D-MEM. The tissue was minced into fine fragments using a scissor, and subse-
quently transferred in a 15-ml centrifuge tube containing 2 ml of 1 mg/ml Collagenase II dis-
solved in serum free D-MEM.
After 2–3 hours at 37°C in a CO2 incubator, dissociated clumps of cells and loose cells were
washed in cold serum free D-MEM to remove Collagenase and finally transferred in a 25-cm2
culture flask with 5 ml of complete D-MEMmedium (15% Fetal Calf Serum, 1x L-Glutamine,
1x Penicillin/streptomycin) and incubated in CO2-incubator.
After 3–4 days of culture, when cellular growth became evident, medium was replaced twice
per week. When several colonies were well expanded with rounded up mitotic cells and 60–
70% confluence was reached, subcultures were set up splitting primary culture by Trypsin-
EDTA solution cell detachment.
Molecular studies were performed on cell cultures obtained from the split of primary cul-
tures (first subculture, 1st passage) or on cell cultures obtained from the splitting of confluent
first subcultures (2nd passage).
Quantification of Cell Number
The reported number of primary cells was determined by counting. Supernatants (containing
dead/floating cells) were collected, and the remaining adherent cells were detached by Tryp-
sin/EDTA (Sigma-Aldrich). Cell pellets were resuspended in 1X PBS and 10 μl were mixed
with an equal volume of 0.01% trypan blue solution. Viable cells (unstained, trypan blue
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negative cells) and dead cells (stained, trypan blue positive cells) were counted with a phase
contrast microscope.
Cell Proliferation Assay (WST-1)
Cell proliferation was determined using the Cell Proliferation Reagent WST-1 (Roche, Mann-
heim, Germany) as per manufacturer’s instructions. Briefly, cells were seeded into 96-well
plates one day before treatment. After 12h, 24h, 36h or 48h of drugs (or DMSO) exposure,
10 μl of the Cell Proliferation Reagent WST-1 were added to each well and incubated at 37°C
in a humidified incubator for 1h. The absorbance was measured on a microplate reader (Bio-
Tek, Seattle, USA) at 450/655 nm. Each assay was performed in 6 replicates and the experiment
was repeated six times. The proliferation index was calculated as the ratio of WST-1 absor-
bance of treated cells at the indicated time point (12h, 24h, 36h or 48h) to WST-1 absorbance
of the same experimental group at 0h.
Immunoblot Analysis
Immunoblotting analyses were performed according to Cell Signaling Technology instructions
(Beverly, USA). Briefly, cells were homogenized in 1X lysis buffer (50 mM Tris-HCl pH 7.4; 5
mM EDTA; 250 mMNaCl; 0.1% Triton X-100) supplemented with protease and phosphatase
inhibitors (1 mM PMSF; 1.5 μM pepstatin A; 2 μM leupeptin; 10 μg/ml aprotinin, 5 mMNaF; 1
mMNa3VO4). 15 to 20 μg of protein extracts from each sample were denatured in 5x Laemmli
sample buffer and loaded into an SDS-polyacrylamide gel for western blot analysis. Western
blots were performed using polyclonal anti-β-Actin (Sigma-Aldrich; Cat N° A 2066; dil:
1:10000; rabbit; antigen: C11 [11 aa in C- terminal]), monoclonal anti-phospho-Akt (Thr308)
(Cell Signaling Technology; Cat N° #2965, dil: 1:250; rabbit; antigen: synthetic phospho-
peptide [KLH-coupled] corresponding to residues around Thr308 of a mouse Akt), polyclonal
anti-phospho-Akt (Ser473) (Cell Signaling Technology; Cat N° 9271; dil: 1:250; rabbit; antigen:
synthetic phospho-peptide [KLH-coupled] corresponding to residues around Ser473 of a
mouse Akt), polyclonal anti-Akt (Cell Signaling Technology; Cat N° #9272; dil: 1:500; rabbit;
antigen: synthetic peptide [KLH-coupled] derived from carboxy-terminal sequence of a mouse
Akt), polyclonal anti-phospho-p70S6K (Ser371) (Cell Signaling Technology; Cat N° #9208; dil:
1:250; rabbit; antigen: synthetic phospho-peptide [KLH-coupled] corresponding to residues
around Ser371 of humane p70S6 kinase). Western blots were developed with the ECL-plus
chemiluminescence reagent (GE Healthcare, Uppsala, Sweden) as per manufacturer's
instructions.
Statistical Analysis
Statistical significance of the results was analyzed using Student’s t-test. P<0.05 was considered
statistically significant.
Results
Patients and clinical findings
Patient 1. Patient 1, a female aged 10 years and 4 months, is the first of two children of a
healthy 38-year-old woman and a non-consanguineous 48-year-old man, whose family history
was unremarkable. She was conceived naturally. The fetal ultrasound scan at gestational week
(gw) 12 was normal, while at gw 21 a choroid plexus cyst and echogenic intracardiac focus
were detected, the biparietal diameter was at the 95th centile at gw 21 and>95th centile at gw
33 with normal cerebral morphology. She was born at the 34th gw with a weight of 3080 g (90-
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97th centile), length of 49 cm (90th centile) and head circumference of 35.6 cm (97th centile). At
birth, a diffuse capillary malformation involving the trunk and limbs was observed, associated
with cutaneous syndactyly of the 2nd and 3rd toes (Fig 1a). During the first year of life, a plantar
epidermal nevus and a small hemangioma, which subsequently disappeared, were observed, to-
gether with left hemihyperplasia (detected at the age of 3 months).
Cardiac and abdominal ultrasound scans were repeatedly normal. Brain MRI scans detected
increased peritrigonal signal of white matter at the age of 10 months and focal hemimegalence-
phaly with perisylvian polymicrogyria at the age of 7 years. From the age of 7 years, the girl had
episodes of generalized tonic-clonic seizures refractory to antiepileptic therapy. She suffers
from mild cognitive impairment and attention deficit disorder, and in the last years had temper
tantrums and angry outbursts.
Fig 1. Clinical andmutational spectrum of the three index cases. a Patient 1, clinically diagnosed with MCAP, showing diffuse capillary malformation at
the age of 2 months and cutaneous syndactyly between the 2nd and 3rd toes. The PIK3CA c.241 G>A [p.E81K] mutation detected by Sanger sequencing in
affected cells and tissues of patient 1 showed varying levels of the mutant allele depending on the tissue tested. The mutation was absent in the patient's
blood and in her parents. bMacrodactyly of the right 4th finger in patient 2, diagnosed with FAO, at the age of 17 years. Sequence of PIK3CA exon 20 in blood
and cultured fibroblasts obtained from patient 2 showing that the mutation is undetectable in these samples. c Patient 3, at the age of 15 months before
surgical intervention; note the disproportion of the left 2nd and 3rd fingers and the subcutaneous mass at the left deltoid region. Sanger sequencing validation
of the c.3140 A>T [p.H1047L] mutation detected with targeted deep sequencing in the biopsy from the 2nd finger of patient 3. d List of samples and mutations
detected with targeted deep sequencing. Coverage indicates the mean average of reads on target in the regions of interest (ROI) while frequency denotes
the percentage of reads with the mutation.
doi:10.1371/journal.pone.0123092.g001
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On physical examination at the age of 10 years and 4 months, her weight was 35 kg (25th-
50th centile), height 138 cm (25th-50th centile) and head circumference 60 cm (+ 5.2 SD). She
had left hemihyperplasia, involving face, trunk and limbs (mainly legs) with diffusely soft and
thick irregularly marbled skin and prominent capillaries and veins on the trunk, abdomen and
limbs. Three small (diameter<0.5 cm) achromic spots were observed on the trunk. Her 3rd
right finger was significantly larger than the contralateral one and she had a bilateral proximal
4/5 cutaneous syndactyly of the 2nd and 3rd toes. Besides macrosomia, she had dysmorphic fea-
tures including malar hypoplasia, hypertelorism (inner canthal distance>97th centile, palpe-
bral length + 1 SD), long philtrum (>97th centile) and high palate, and S-shaped scoliosis.
Patient 2. Patient 2, the only daughter of healthy non-consanguineous parents, presented
to our observation at 12 years of age with a history of macrodactyly of the right 4th finger diag-
nosed at birth (Fig 1b). Histological examination carried out after surgical excisions performed
at 3 and 5 years of age showed fibrolipomatous tissue. At 6 years of age, disease recurrence was
observed, with two nodular areas (14 and 11.2 mm in diameter) revealed by ultrasound scan of
the right hand soft tissues. Such areas, located adjacent to the shaft of the middle and distal
phalanges, showed uneven distribution and no evidence of bone overgrowth or distortion at X-
ray examination. No development of further lesions was observed at follow-up at age 18, except
for a small angioma between the 4th and 5th right metacarpal bones, and increased volume of
the already existing fibrolipomas of the right 4th finger.
Patient 3. The proband is the first and only son of healthy, non-consanguineous parents.
At birth, macrodactyly of the left 2nd and 3rd fingers was noted. Radiological examination
showed that overgrowth involved the soft tissues and all skeletal segments (phalangeal and
metacarpal bones) of the affected rays. Thus, a provisional diagnosis of apparently isolated true
congenital macrodactyly was done and a periodical clinical follow-up was suggested. Over
time, the two enlarged fingers showed disproportionate overgrowth. Moreover, at 6 months of
age, a soft swelling appeared at the left deltoid region, which was sonographically compatible
with a subcutaneous mass of adipose tissue, and, at 10 months of age, a slight overgrowth of
the left arm and forearm was noted. These clinical signs suggested a diagnostic hypothesis of
Proteus-like syndrome. Because of the negative functional and postural consequences of exces-
sive volume and weight of the abnormal fingers, a surgical intervention was performed when
the proband was 1 year and 3 months old to remove the 2nd and 3rd left fingers by amputation
(Fig 1c). Skin biopsies from the affected regions were obtained during this procedure. So far,
surveillance measures revealed no abnormalities. Psychomotor development seems to be nor-
mal and physical examination revealed no significant craniofacial dysmorphism.
Molecular and biochemical analyses
Mutational analysis of PIK3CA exons and adjacent intronic regions was performed by Sanger se-
quencing methods on genomic DNA isolated from blood samples, tissue biopsies, and cultured
dermal fibroblasts. No pathogenic variants were found, except for the point mutation c.241
G>A [p.E81K] in PIK3CA exon 1 detected in patient 1. This mutation was identified in hetero-
zygosity in hair follicles, saliva, left leg biopsy, and left and right leg cultured dermal fibroblasts
of the proband, but was undetectable in the patient's blood and in her parents (Fig 1a).
Considering the limited sensitivity of Sanger sequencing for detecting low-level mosaic muta-
tions, we performed targeted deep sequencing of 21 selected genes involved in the PI3K/AKT/
mTOR pathway both in blood and tissue/biopsy/cell culture samples of the three patients.
The mean coverage depth per sample was 1900X with a mean percentage of reads on target
of 93.75%. The percentage of ROI with a minimum coverage of 200X was 97.22%, see Table C
in S1 File.
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This approach confirmed the presence of the c.241 G>A [p.E81K] mutation in the right
and left leg biopsies of patient 1, with mutant allele frequencies of 9% and 21.5%, respectively
(Fig 1d).
In both patients with a clinical diagnosis of FAO (patients 2 and 3), targeted deep sequenc-
ing analysis led to the identification of a PIK3CAmutation in primary fibroblasts samples only.
Specifically, a c.3140 A>G [p.H1047R] mutation was identified in cultured dermal fibroblasts
of patient 2 with a frequency of 9.1% (74/811 reads) (Fig 1d) and a c.3140 A>T [p.H1047L]
mutation was identified in the 2nd finger tissue biopsy of patient 3 with a frequency of 15.5%
(116/746 reads) (Fig 1d). As shown in Fig 1b and 1c, respectively, the c.3140 A>G [p.H1047R]
mutation was undetectable by Sanger sequencing, whereas the c.3140 A>T [p.H1047L] muta-
tion was visible with this method in DNA derived from fibroblast cultures, but was absent in
blood samples (data not shown).
PIK3CAmutations have been previously identified in several types of cancer, where they
overactivate the PI3K/AKT/mTOR signaling in the absence of growth factors [8,9]. Thus, to
functionally characterize these mutations in our patients, we cultured primary dermal fibroblasts
from skin biopsies of overgrowth lesions in the absence of serum. According to our immuno-
blotting results (Fig 2a and 2b), mutant cells (fibroblasts from biopsy of patient 2, and from left
and right leg biopsies of patient 1) showed increased levels of phosphorylated AKT at threonine
308, a residue targeted by PI3K in a direct or indirect (through PDK1) manner, when compared
to IMR90 primary human normal fibroblasts. Moreover, patients’ cells showed increased phos-
phorylation of another AKT residue, serine 473, which is targeted by the TORC2 complex
(mTOR/Rictor) in a PI3K-dependent manner [10,11]. In order to fully characterize the PI3K/
AKT/mTOR cascade, we also evaluated the phosphorylation status of p70S6K, a direct substrate
of the TORC1 complex (mTOR/Raptor). Our results showed that phosphorylation of serine
371, was significantly increased in overgrowing cells compared to normal healthy cells.
To complete the functional characterization of our patients’ primary fibroblasts, we treated
these cells with the PI3K inhibitors wortmannin or LY294002 in the absence of growth factor
stimulation. As shown in Fig 2b, overactivation of the PI3K/AKT/mTOR pathway was abrogat-
ed by pharmacological inhibition of PI3K in all patients tested as shown by the evaluation of
the phosphorylation status of p-AKT and p-p70S6K. Importantly, patient-derived fibroblasts
showed the ability to grow in culture even in the absence of growth factors, thus mimicking
in vivo overgrowth features, while IMR90 primary human normal fibroblasts failed to prolifer-
ate in serum starvation conditions (Fig 2c). Moreover, growth factor-independent proliferation
in vitro was significantly decreased by the pharmacological blockade of PI3K by both wortman-
nin and LY294002 in affected cells (Fig 2c), suggesting that this approach could be beneficial in
overgrowth patients.
Discussion
Our data support the hypothesis that PIK3CAmutations can be responsible for a wide clinical
spectrum of segmental overgrowth disorders. Identical mutations have been found in pheno-
typically distinct disorders; however, to date any correlation with genotype is suggested but not
confirmed [12]. The c.241 G>A [p.E81K] mutation identified in a patient with MCAP, patient
1, has been described previously in only one case of MCAP [2]. This mutation involves the resi-
due 81 in the Ras-binding domain of PI3K and to our knowledge no functional analysis for this
mutation has been ever performed on cells of affected patients.
According to Keppler-Nereuil [7] this patient should be categorized as PROS-A.
The PIK3CA c.3140 A>G [p.H1047R] mosaic mutation identified in patient 2 with over-
growth confined only to the right 4th finger diagnosed at birth, has been observed in patients
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Fig 2. Overactivation of the PI3K/Akt pathway is abrogated by pharmacological inhibition of PI3K in all patients tested. a The indicated values are
the result of the densitometric analysis of the phosphorylated forms of Akt and p70S6K normalized against total Akt and the loading control, respectively. The
presented results are representative of at least three independent sets of experiments (bars represent standard deviation of the mean). b Immunoblot
analysis of phospho-Akt (Ser473), phospho-Akt (Thr308), total Akt and phospho-p70S6K (Ser371) in mutant cells (fibroblasts from biopsies of FAO patient 2,
and from left [L] and right [R] leg biopsies of MCAP patient 1) compared to IMR90 primary human normal fibroblasts (Ctrl). β-Actin was used as a loading
control. Cells were treated with the PI3K inhibitor wortmannin (10μM) for 24 hours in the absence of growth factor stimulation. The presented results are
representative of at least three independent sets of experiments. c Patients' affected cells are dependent on PI3K activity for proliferation. Primary fibroblasts
obtained from biopsies were cultured in the presence or absence of wortmannin (10μM) and LY294002 (25μM). At the indicated time points, the proliferation
index was determined using the WST-1 assay. The results were also confirmed by cell counting with trypan blue staining (data not shown). Each assay was
performed in 6 replicates and the experiment was repeated six times. Statistical analysis was performed using Student’s t-tail test; *P<0.05, which was
considered statistically significant (bars represent standard deviation of the mean).
doi:10.1371/journal.pone.0123092.g002
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with KTS, CLOVES and very severe FAO, but also in cases of isolated macrodactyly [13]. On
the basis of the clinical spectrum of this patient (see results), after the positive testing for
PIK3CA mutation, this patient would be classified as PROS B. It is worth noting that the
PIK3CA c.3140 A>G [p.H1047R] change is the most common cancer-associated PIK3CAmu-
tation [8,9]. However, in affected tissues of overgrowth disorder patients, it is isolated and asso-
ciated to a variable mutation burden, as opposed to what happens in a tumor, where it is one of
several somatic mutations.
Similarly, the c.3140 A>T [p.H1047L] mutation identified in patient 3, with clinical presen-
tation consistent with FAO, has been already described in FAO and in isolated macrodactyly
type I cases, and was also reported in more than 130 human cancers in the COSMIC Database.
The initial classification of this patient at referral would have been PROS B, however, after clin-
ical follow up, he was more precisely matching the PROS A presentation.
Our functional studies on primary patient-derived fibroblasts showed overactivation of the
PI3K pathway and PI3K-dependent proliferation in affected cells for all mutations analyzed.
Indeed, patients’derived cells were able to grow in vitro in the absence of growth factors and
mitogens, while displaying a significantly reduced proliferation rate upon PI3K pharmacologi-
cal inhibition by both wortmannin and LY294002. Very recent reports have demonstrated that
oncogenic PIK3CA mutations cause activation of PI3K pathway and proliferative advantage in
cells derived from lymphatic malformations [14,15]. Our data, show that the two mutations
functionally studied [H1047R, E81K] behave similarly in PROS patient-derived fibroblast.
No malignancies were identified in our patients. Although an increased cancer risk cannot
be ruled out in patients with somatic PIK3CAmutations, data are currently very limited. This
is not surprising considering that only in recent years researchers began to identify mutations
associated with these disorders, which were often misdiagnosed and superficially classified as
Proteus or Proteus-like syndromes [16]. Keppler-Noreuil et al. [12] described a patient diag-
nosed with FAO harboring a mosaic c.3140 A>T [p.H1047L] mutation that developed prema-
lignant features of nephrogenic rests and a second patient, diagnosed with CLOVES, who had
an ovarian cystadenoma; In addition, Kurek et al. [4] reported the case of a CLOVES patient
with a mosaic c.3140 A>G [p.H1047R] mutation, who was affected by Wilms' tumor. In an-
other report, two cases of Wilms' tumor, one case of leukemia, two cases of meningioma and
one case of medulloblastoma were described, respectively, in five MCAP and one MPHH pa-
tient. However, these patients' diagnoses were merely clinical, with no molecular characteriza-
tion of the underlying disorders [2].
Surgical debulking and orthopedic procedures are the only treatments currently available
for patients with segmental overgrowth syndromes [16,17]. However, considering that the in-
vestigation of small molecule inhibitors of the PI3K signaling network is a promising area of
oncology drug development, in the next few years these patients may well benefit from the re-
sults of completed and ongoing clinical trials on PI3K inhibitors in cancer therapy. For exam-
ple, an improved wortmannin chemical analog, PX-866, displayed antitumor activity in
preclinical models and is currently being tested in various clinical trials [18]. For all of these
reasons, PROS patients might be regarded as very appropriate candidates for enrollment in tri-
als based on PI3K inhibitors. In fact, they display an ideal "clean" cellular setting, as they carry
only a single PIK3CAmutation while lacking the host of somatic mutations that usually char-
acterize tumors and that can interfere with/modulate the complex mechanisms regulating
PI3K/AKT/mTOR signaling. On the other side, they would need long-term therapies and thus
should be treated with drugs with very limited and acceptable side effects.
The results presented in this study, strengthen the idea that patients with these rare and
often neglected syndromes, may represent the target of future trials using clinically available in-
hibitors of the PI3K/AKT/MTOR pathways.
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